CLDX Celldex Therapeutics Inc.

2.69
+0.07  (+3%)
Previous Close 2.62
Open 2.62
Price To Book 0.61
Market Cap 50,943,449
Shares 18,938,085
Volume 375,816
Short Ratio
Av. Daily Volume 418,275
Stock charts supplied by TradingView

NewsSee all news

  1. Celldex Provides Corporate Update and Reports First Quarter 2020 Results

    HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. "Despite the ongoing challenges

  2. Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

    HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with

  3. Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

    HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. "We are pleased that

  4. Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

    HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal

  5. Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

    HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. "Celldex achieved a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial continues to enrol as of May 6, 2020.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 1 presentation at SITC November 7, 2019.
CDX-1140
Solid tumors
Phase 1 presentation at EAACI June 6, 2020.
CDX-0159
Healthy volunteers
Phase 1 trial to be initiated 2H 2020.
CDX-527
Advanced cancers

Latest News

  1. Celldex Provides Corporate Update and Reports First Quarter 2020 Results

    HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. "Despite the ongoing challenges

  2. Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

    HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with

  3. Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

    HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. "We are pleased that

  4. Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

    HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal

  5. Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

    HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. "Celldex achieved a

  6. Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

    -CDX-0159 IND accepted; Phase 1 study to start by YE 2019--CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the

  7. CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

    -Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity--Clinical trial collaboration with Merck

  8. Celldex Therapeutics Announces Upcoming Data Presentations

    HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and

  9. Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

    HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder,